Neuropharmacological & Biochemical Evaluation for Schizophrenia - Gautam Palit - 書籍 - LAP LAMBERT Academic Publishing - 9783659346330 - 2013年2月13日
カバー画像とタイトルが一致しない場合、正しいのはタイトルです

Neuropharmacological & Biochemical Evaluation for Schizophrenia


商品が入荷したらメールで通知を受け取る
プロフィールはありますか? ログイン
クリスマスプレゼントは1月31日まで返品可能です
Gautam Palit の新しいリリースのお知らせを受け取る
iMusicのウィッシュリストに追加

まだ評価がありません

Schizophrenia a chronic, debilitating psychiatric disorder comprises of positive and negative symptoms along with cognitive and attention impairments. Antipsychotic drugs available in the market for treatment of schizophrenia have either been unable to treat all the symptoms of schizophrenia or accompany a lot of side-effects. Ketamine, a NMDA receptor antagonist was used to model psychotic symptoms in mice. Herbal compounds (CDRB01 and CDRP01) normalized the ketamine induced increased NR1A protein expression, reduced acetylcholinesterase activity as well as monoamine oxidase activity but did not show any extrapyramidal side effects. Estimation of brain neurotransmitter level revealed that both compounds reduced DA and 5-HT content in the cortex, striatal and hippocampal regions. CDR-B01 was effective in ameliorating positive, negative as well as cognitive dysfunctions induced by ketamine. Whereas compound CDRP01 significantly attenuated ketamine induced increased D1 receptor expression but had no significant effects on D2 expression, showed efficacy in the negative and cognitive symptoms only. They normalized GSH level, reduced lipid peroxidation & nitrite but increased SOD level.

メディア 書籍     Paperback Book   (ソフトカバーで背表紙を接着した本)
リリース済み 2013年2月13日
ISBN13 9783659346330
出版社 LAP LAMBERT Academic Publishing
ページ数 156
寸法 150 × 9 × 225 mm   ·   235 g
言語 英語